Modality
siRNA
MOA
KRASG12Di
Target
SGLT2
Pathway
Sphingolipid
RSV
Development Pipeline
Preclinical
~Sep 2010
→ ~Dec 2011
Phase 1
~Mar 2012
→ ~Jun 2013
Phase 2
~Sep 2013
→ ~Dec 2014
Phase 3
~Mar 2015
→ ~Jun 2016
NDA/BLA
~Sep 2016
→ ~Dec 2017
Approved
Mar 2018
→ Oct 2030
ApprovedCurrent
NCT08963152
2,104 pts·RSV
2025-09→2030-10·Not yet recruiting
NCT07091858
908 pts·RSV
2024-02→2026-01·Recruiting
NCT03167152
556 pts·RSV
2018-03→TBD·Terminated
+1 more trial
4,184 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-01-222mo agoPh3 Readout· RSV
2030-10-154.5y awayPh3 Readout· RSV
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Approved
Recruit…
Approved
Active
Approved
Not yet…
Catalysts
Ph3 Readout
2026-01-22 · 2mo ago
RSV
Ph3 Readout
2030-10-15 · 4.5y away
RSV
RecruitingActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08963152 | Approved | RSV | Not yet recr... | 2104 | OS |
| NCT07091858 | Approved | RSV | Recruiting | 908 | FEV1 |
| NCT03167152 | Approved | RSV | Terminated | 556 | HbA1c |
| NCT05838821 | Approved | RSV | Active | 616 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |